S&P 500   3,855.05 (-1.79%)
DOW   31,579.41 (-1.20%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   232.10 (-1.04%)
FB   257.92 (-2.42%)
GOOGL   2,039.36 (-2.13%)
AMZN   3,102.09 (-1.82%)
TSLA   702.18 (-5.37%)
NVDA   539.13 (-7.04%)
BABA   244.59 (-2.30%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.27 (-6.92%)
AMD   83.65 (-3.78%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.41 (-1.57%)
BA   221.11 (-3.59%)
NFLX   541.93 (-2.07%)
BAC   36.37 (-0.03%)
S&P 500   3,855.05 (-1.79%)
DOW   31,579.41 (-1.20%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   232.10 (-1.04%)
FB   257.92 (-2.42%)
GOOGL   2,039.36 (-2.13%)
AMZN   3,102.09 (-1.82%)
TSLA   702.18 (-5.37%)
NVDA   539.13 (-7.04%)
BABA   244.59 (-2.30%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.27 (-6.92%)
AMD   83.65 (-3.78%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.41 (-1.57%)
BA   221.11 (-3.59%)
NFLX   541.93 (-2.07%)
BAC   36.37 (-0.03%)
S&P 500   3,855.05 (-1.79%)
DOW   31,579.41 (-1.20%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   232.10 (-1.04%)
FB   257.92 (-2.42%)
GOOGL   2,039.36 (-2.13%)
AMZN   3,102.09 (-1.82%)
TSLA   702.18 (-5.37%)
NVDA   539.13 (-7.04%)
BABA   244.59 (-2.30%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.27 (-6.92%)
AMD   83.65 (-3.78%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.41 (-1.57%)
BA   221.11 (-3.59%)
NFLX   541.93 (-2.07%)
BAC   36.37 (-0.03%)
S&P 500   3,855.05 (-1.79%)
DOW   31,579.41 (-1.20%)
QQQ   316.84 (-2.25%)
AAPL   123.01 (-1.87%)
MSFT   232.10 (-1.04%)
FB   257.92 (-2.42%)
GOOGL   2,039.36 (-2.13%)
AMZN   3,102.09 (-1.82%)
TSLA   702.18 (-5.37%)
NVDA   539.13 (-7.04%)
BABA   244.59 (-2.30%)
CGC   33.85 (-4.92%)
GE   12.91 (-1.60%)
MU   90.06 (-2.66%)
NIO   48.27 (-6.92%)
AMD   83.65 (-3.78%)
T   28.75 (-2.14%)
F   11.97 (-2.44%)
ACB   11.18 (-3.95%)
DIS   194.41 (-1.57%)
BA   221.11 (-3.59%)
NFLX   541.93 (-2.07%)
BAC   36.37 (-0.03%)
Log in
NASDAQ:PHIO

Phio Pharmaceuticals Stock Forecast, Price & News

$3.27
-0.02 (-0.61 %)
(As of 02/25/2021 02:22 PM ET)
Add
Compare
Today's Range
$3.16
Now: $3.27
$3.35
50-Day Range
$2.76
MA: $3.23
$4.05
52-Week Range
$1.60
Now: $3.27
$6.48
Volume9,099 shs
Average Volume1.58 million shs
Market Capitalization$46.12 million
P/E RatioN/A
Dividend YieldN/A
Beta2.31
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Headlines

Phio Pharmaceuticals Corp. Common Stock (PHIO)
October 28, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHIO
CUSIPN/A
CIKN/A
Phone508-767-3861
Employees11
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Book Value$8.59 per share

Profitability

Net Income$-8,910,000.00

Miscellaneous

Market Cap$46.12 million
Next Earnings Date3/25/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.25 out of 5 stars

Medical Sector

765th out of 1,957 stocks

Pharmaceutical Preparations Industry

379th out of 771 stocks

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
$3.27
-0.02 (-0.61 %)
(As of 02/25/2021 02:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PHIO News and Ratings via Email

Sign-up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions

Is Phio Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Phio Pharmaceuticals stock.
View analyst ratings for Phio Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Phio Pharmaceuticals?

Wall Street analysts have given Phio Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Phio Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Phio Pharmaceuticals?

Phio Pharmaceuticals saw a increase in short interest in January. As of January 29th, there was short interest totaling 1,290,000 shares, an increase of 152.2% from the January 14th total of 511,400 shares. Based on an average daily trading volume, of 770,900 shares, the days-to-cover ratio is currently 1.7 days. Approximately 12.7% of the shares of the stock are sold short.
View Phio Pharmaceuticals' Short Interest
.

When is Phio Pharmaceuticals' next earnings date?

Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for Phio Pharmaceuticals
.

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) released its quarterly earnings results on Sunday, November, 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.02.
View Phio Pharmaceuticals' earnings history
.

How has Phio Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Phio Pharmaceuticals' stock was trading at $2.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PHIO shares have increased by 18.1% and is now trading at $3.27.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PHIO?

1 equities research analysts have issued 1-year price objectives for Phio Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Phio Pharmaceuticals' share price to reach $4.00 in the next year. This suggests a possible upside of 22.3% from the stock's current price.
View analysts' price targets for Phio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Phio Pharmaceuticals' key executives?

Phio Pharmaceuticals' management team includes the following people:
  • Dr. Gerrit Dispersyn Ph.D., Dr. Med. Sc, Pres, CEO & Director (Age 46, Pay $541.72k)
  • Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 35)

Who are some of Phio Pharmaceuticals' key competitors?

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST).

What is Phio Pharmaceuticals' stock symbol?

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

Who are Phio Pharmaceuticals' major shareholders?

Phio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (1.75%).
View institutional ownership trends for Phio Pharmaceuticals
.

Which major investors are buying Phio Pharmaceuticals stock?

PHIO stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP.
View insider buying and selling activity for Phio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phio Pharmaceuticals' stock price today?

One share of PHIO stock can currently be purchased for approximately $3.27.

How much money does Phio Pharmaceuticals make?

Phio Pharmaceuticals has a market capitalization of $46.12 million and generates $20,000.00 in revenue each year. The company earns $-8,910,000.00 in net income (profit) each year or ($19.33) on an earnings per share basis.

How many employees does Phio Pharmaceuticals have?

Phio Pharmaceuticals employs 11 workers across the globe.

What is Phio Pharmaceuticals' official website?

The official website for Phio Pharmaceuticals is phiopharma.com.

Where are Phio Pharmaceuticals' headquarters?

Phio Pharmaceuticals is headquartered at 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752.

How can I contact Phio Pharmaceuticals?

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at 508-767-3861 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.